One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Gamida Cell Ltd. logo
Gamida Cell Ltd. GMDA

Gamida Cell Ltd. Financial Statements 2021-2011 | GMDA

Annual Financial Statements Gamida Cell Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 353 M 152 M 359 M - - - - - - -

Shares

- 43.8 M 33.7 M 24.9 M - - - - - - -

Historical Prices

2.54 8.39 4.3 9.94 - - - - - - -

Net Income

- -72.7 M -34.4 M -52.9 M -19 M -22.7 M - - - - -

Operating Income

- -62.3 M -48.2 M -33.6 M -19.5 M -23.7 M - - - - -

EBITDA

- -62.7 M -46.1 M -33.4 M -19.3 M -23.6 M - - - - -

Operating Expenses

- - 48.2 M 33.6 M 19.5 M 23.7 M - - - - -

General and Administrative Expenses

- 19.8 M 11.2 M 11.6 M 4.47 M 4.61 M - - - - -

All numbers in USD currency

Quarterly Income Statement Gamida Cell Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - - - - - - - - - - - 26 M - - - 690 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - - -19.6 M -21.3 M - - -14.8 M -15.1 M - - - 5.96 M - - - -13.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - -23.1 M -22.5 M - - -15.1 M -12.8 M - - - -10.8 M - - - -9.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - -23.1 M -22.5 M - - -15.1 M -12.8 M - - - -10.8 M - - - -9.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - 4.77 M 3.82 M - - 2.69 M 2.5 M - - - 2.45 M - - - 2.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Gamida Cell Ltd. GMDA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Gamida Cell Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.09 3.81 % $ 6.86 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.95 -3.3 % $ 95.3 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.03 1.78 % $ 3.59 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 58.93 1.57 % $ 7.88 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 55.62 -0.59 % $ 10.7 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.48 0.79 % $ 1.96 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.75 2.18 % $ 45.8 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 2.36 15.44 % $ 5.5 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.49 -2.35 % $ 196 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 21.65 -3.5 % $ 1.24 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 25.41 1.48 % $ 1.5 B usaUSA
Xencor Xencor
XNCR
$ 29.2 15.95 % $ 2.17 B usaUSA
Annexon Annexon
ANNX
$ 3.71 -1.2 % $ 575 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.71 -4.21 % $ 2.82 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.3 -2.08 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 12.43 1.22 % $ 15 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.2 -0.16 % $ 740 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 516.39 -1.44 % $ 132 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.24 -3.72 % $ 710 M britainBritain
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.77 -0.39 % $ 1.14 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.47 1.29 % $ 1.19 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.19 -1.07 % $ 304 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.4 0.05 % $ 213 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.37 0.44 % $ 2.91 M israelIsrael
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 0.36 -10.09 % $ 26.4 K usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 1.87 -3.11 % $ 52.2 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 10.12 0.4 % $ 289 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 2.04 2.0 % $ 128 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 13.76 4.13 % $ 11.5 B indiaIndia
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 9.91 0.71 % $ 271 M israelIsrael
Sanofi Sanofi
SNY
$ 41.77 0.41 % $ 51 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 31.74 1.73 % $ 4.04 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 1.15 2.23 % $ 767 M usaUSA
Gossamer Bio Gossamer Bio
GOSS
$ 9.2 -4.27 % $ 2.1 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.14 -2.56 % $ 61.2 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.3 -0.46 % $ 50 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.55 0.85 % $ 286 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 17.02 0.98 % $ 2.29 B canadaCanada
iBio iBio
IBIO
$ 0.71 -1.28 % $ 73.9 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 10.21 -0.37 % $ 92.2 M usaUSA